Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.30 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16213581 | 0.84 | MAPK1 (0.89) | MAPK1BRD4 | |
| Trifluoroacetic Acid SCHEMBL16213585 | 0.84 | MAPK1 (0.89) | MAPK1BRD4 | |
| SCHEMBL16213590 | 0.83 | MAPK1 (0.70) | MAPK1BRD4 | |
| SCHEMBL16213592 | 0.83 | MAPK1 (0.70) | MAPK1BRD4 | |
| SCHEMBL19548197 | 0.81 | MAPK1 (0.51) | MAPK1BRD4ADORA3 | |
| SCHEMBL16213532 | 0.81 | MAPK1 (0.51) | MAPK1BRD4ADORA3 | |
| SCHEMBL17555401 | 0.81 | MAPK1 (1.00) | MAPK1BRD4 | |
| SCHEMBL16224842 | 0.81 | MAPK1 (1.00) | MAPK1BRD4 | |
| SCHEMBL16213099 | 0.79 | MAPK1 (0.68) | MAPK1 | |
| Trifluoroacetic Acid SCHEMBL16213533 | 0.67 | MAPK1 (0.66) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-08 | — | — | US | disclosed |
| US-10065967-B2 | Compounds that are ERK inhibitors | Merck, Sharp & Dohme Corp. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9745307-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2991654-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | MAPK1 1/4885LPAR1 1449/4885BRD4 1881/4885 |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885LPAR1 1214/4885BRD4 1714/4885 |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885LPAR1 1214/4885BRD4 1714/4885 |
| US-10065967-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | MAPK1 1/4885LPAR1 1449/4885BRD4 1881/4885 |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAP3K20, MAPK6 | MAPK1 1/4885LPAR1 1919/4885BRD4 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.